ALDEYRA THERAPEUTICS INC (ALDX) Stock Price, Quote, News and Overview
NASDAQ:ALDX - Nasdaq - US01438T1060 - Common Stock - Currency: USD
ALDX Quote, Performance and Key Statistics
6.69
-0.03 (-0.45%)
The current stock price of ALDX is 6.69 USD. In the past month the price increased by 33%. In the past year, price increased by 91.69%.
ALDX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ALDX
Company Profile
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2014-05-02. The firm's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Company Info
ALDEYRA THERAPEUTICS INC
131 Hartwell Avenue, Suite 320
Lexington MASSACHUSETTS 02421 US
CEO: Todd C. Brady
Employees: 10
Company Website: https://www.aldeyra.com/
Investor Relations: https://ir.aldeyra.com/
Phone: 17817614904
ALDEYRA THERAPEUTICS INC / ALDX FAQ
What is the stock price of ALDEYRA THERAPEUTICS INC today?
The current stock price of ALDX is 6.69 USD. The price decreased by -0.45% in the last trading session.
What is the ticker symbol for ALDEYRA THERAPEUTICS INC stock?
The exchange symbol of ALDEYRA THERAPEUTICS INC is ALDX and it is listed on the Nasdaq exchange.
On which exchange is ALDX stock listed?
ALDX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALDEYRA THERAPEUTICS INC stock?
14 analysts have analysed ALDX and the average price target is 10.49 USD. This implies a price increase of 56.82% is expected in the next year compared to the current price of 6.69. Check the ALDEYRA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALDEYRA THERAPEUTICS INC worth?
ALDEYRA THERAPEUTICS INC (ALDX) has a market capitalization of 398.39M USD. This makes ALDX a Small Cap stock.
How many employees does ALDEYRA THERAPEUTICS INC have?
ALDEYRA THERAPEUTICS INC (ALDX) currently has 10 employees.
What are the support and resistance levels for ALDEYRA THERAPEUTICS INC (ALDX) stock?
ALDEYRA THERAPEUTICS INC (ALDX) has a support level at 5.19. Check the full technical report for a detailed analysis of ALDX support and resistance levels.
Is ALDEYRA THERAPEUTICS INC (ALDX) expected to grow?
The Revenue of ALDEYRA THERAPEUTICS INC (ALDX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ALDX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALDEYRA THERAPEUTICS INC (ALDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALDX, evaluating the profitability, health, valuation and growth aspects
- ALDEYRA THERAPEUTICS INC (ALDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALDEYRA THERAPEUTICS INC (ALDX) Sales and EPS estimates to see what analysts future expectations are.
- ALDEYRA THERAPEUTICS INC (ALDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALDEYRA THERAPEUTICS INC (ALDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALDEYRA THERAPEUTICS INC (ALDX) Stock Chart to make your own analysis
- ALDEYRA THERAPEUTICS INC (ALDX) Latest news and press-releases to stay up to date.
Does ALDEYRA THERAPEUTICS INC (ALDX) stock pay dividends?
ALDX does not pay a dividend.
When does ALDEYRA THERAPEUTICS INC (ALDX) report earnings?
ALDEYRA THERAPEUTICS INC (ALDX) will report earnings on 2025-03-05, after the market close.
What is the Price/Earnings (PE) ratio of ALDEYRA THERAPEUTICS INC (ALDX)?
ALDEYRA THERAPEUTICS INC (ALDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.75).
What is the Short Interest ratio of ALDEYRA THERAPEUTICS INC (ALDX) stock?
The outstanding short interest for ALDEYRA THERAPEUTICS INC (ALDX) is 7.52% of its float. Check the ownership tab for more information on the ALDX short interest.
ALDX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ALDX. When comparing the yearly performance of all stocks, ALDX is one of the better performing stocks in the market, outperforming 95.7% of all stocks.
ALDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALDX. While ALDX seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALDX Financial Highlights
Over the last trailing twelve months ALDX reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS increased by 3.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.18% | ||
| ROE | -52.64% | ||
| Debt/Equity | 0.18 |
ALDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 89% to ALDX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -46.23% and a revenue growth -100% for ALDX